Halozyme finishes trial enrollment for bladder cancer drug Chemophase

By Elaine Rigoli

Tampa, Fla., March 6 - Halozyme Therapeutics, Inc. announced Monday that it has completed patient enrollment for its Chemophase phase 1 clinical trial.

Chemophase is a novel investigational recombinant therapeutic being developed to enhance the delivery of chemotherapy.

The initial clinical protocol for Chemophase was designed to evaluate a single intravesical (into the bladder) administration of Chemophase along with the widely used anticancer drug mitomycin in patients with superficial bladder cancer, according to a company news release.

The phase 1 study enrolled five patients with superficial bladder cancer. The objectives of the study were to determine the safety, tolerability and pharmacokinetics of Chemophase administered intravesically with mitomycin, the release said.

According to data from the American Cancer Society, National Cancer Institute, American Urological Association and Southwest Oncology Group Study, more than 100,000 patients have new or recurrent superficial bladder cancer in the United States every year.

Halozyme said all of these patients are potential candidates for Chemophase in the event it is approved as first-line treatment with mitomycin.

Based in San Diego, Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the infertility, palliative care and oncology markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.